{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:07:13Z","timestamp":1781582833693,"version":"3.54.5"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,16]]},"DOI":"10.7759\/cureus.50634","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T22:57:16Z","timestamp":1702767436000},"source":"Crossref","is-referenced-by-count":4,"title":["The Therapeutic Potential of Cannabidiol in Revolutionising Opioid Use Disorder Management"],"prefix":"10.7759","author":[{"given":"Kelvin","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khang Duy Ricky","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000052","article-title":"Long-term course of opioid addiction","volume":"23","author":"Hser YI","year":"2015","unstructured":"Hser YI, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harv Rev Psychiatry. 2015, 23:76-89. 10.1097\/HRP.0000000000000052","journal-title":"Harv Rev Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/biom12030396","article-title":"Biomarkers of the endocannabinoid system in substance use disorders","volume":"12","author":"Navarrete F","year":"2022","unstructured":"Navarrete F, Garc\u00eda-Guti\u00e9rrez MS, Gasparyan A, et al.. Biomarkers of the endocannabinoid system in substance use disorders. Biomolecules. 2022, 12:396. 10.3390\/biom12030396","journal-title":"Biomolecules"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder","volume":"6","author":"Strang J","year":"2020","unstructured":"Strang J, Volkow ND, Degenhardt L, et al.. Opioid use disorder. Nat Rev Dis Primers. 2020, 6:3. 10.1038\/s41572-019-0137-5","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1071\/AH18245","article-title":"Trends in opioid prescribing in Australia: a systematic review","volume":"44","author":"Donovan PJ","year":"2020","unstructured":"Donovan PJ, Arroyo D, Pattullo C, Bell A. Trends in opioid prescribing in Australia: a systematic review. Aust Health Rev. 2020, 44:277-87. 10.1071\/AH18245","journal-title":"Aust Health Rev"},{"key":"ref5","article-title":"Opioid Use Disorder","author":"Dydyk AM","year":"2023","unstructured":"Dydyk AM, Jain NK, Gupta M. Opioid Use Disorder. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.52965\/001c.38672","article-title":"Historical pathways for opioid addiction, withdrawal with traditional and alternative treatment options with ketamine, cannabinoids, and noribogaine: a narrative review","volume":"10","author":"Edinoff AN","year":"2022","unstructured":"Edinoff AN, Wu NW, Nix CA, et al.. Historical pathways for opioid addiction, withdrawal with traditional and alternative treatment options with ketamine, cannabinoids, and noribogaine: a narrative review. Health Psychol Res. 2022, 10:38672. 10.52965\/001c.38672","journal-title":"Health Psychol Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2014.975617","article-title":"Diversion of methadone and buprenorphine from opioid substitution treatment: patients who regularly sell or share their medication","volume":"34","author":"Johnson B","year":"2015","unstructured":"Johnson B, Richert T. Diversion of methadone and buprenorphine from opioid substitution treatment: patients who regularly sell or share their medication. J Addict Dis. 2015, 34:1-17. 10.1080\/10550887.2014.975617","journal-title":"J Addict Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4172\/2155-6105.1000248","article-title":"A comparison of suboxone and methadone in the treatment of opiate addiction","volume":"6","author":"Peddicord AN","year":"2015","unstructured":"Peddicord AN, Bush C, Cruze C. A comparison of suboxone and methadone in the treatment of opiate addiction. J Addict Res Ther. 2015, 6:248. 10.4172\/2155-6105.1000248","journal-title":"J Addict Res Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.12.011","article-title":"Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes","volume":"52","author":"Bentzley BS","year":"2015","unstructured":"Bentzley BS, Barth KS, Back SE, Book SW. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. J Subst Abuse Treat. 2015, 52:48-57. 10.1016\/j.jsat.2014.12.011","journal-title":"J Subst Abuse Treat"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1089\/can.2022.0036","article-title":"Cannabidiol reduced the severity of gastrointestinal symptoms of opioid withdrawal in male and female mice. [PREPRINT]","author":"Scicluna RL","year":"2022","unstructured":"Scicluna RL, Wilson BB, Thelaus SH, Arnold JC, McGregor IS, Bowen MT. Cannabidiol reduced the severity of gastrointestinal symptoms of opioid withdrawal in male and female mice. [PREPRINT]. Cannabis Cannabinoid Res. 2022, 10.1089\/can.2022.0036","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00637-z","article-title":"Buprenorphine treatment for opioid use disorder: an overview","volume":"33","author":"Shulman M","year":"2019","unstructured":"Shulman M, Wai JM, Nunes EV. Buprenorphine treatment for opioid use disorder: an overview. CNS Drugs. 2019, 33:567-80. 10.1007\/s40263-019-00637-z","journal-title":"CNS Drugs"},{"key":"ref12","article-title":"Buprenorphine","author":"Kumar R","year":"2023","unstructured":"Kumar R, Viswanath O, Saadabadi A. Buprenorphine. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7529.1352","article-title":"Is methadone too dangerous for opiate addiction?","volume":"331","author":"Luty J","year":"2005","unstructured":"Luty J, O'Gara C, Sessay M. Is methadone too dangerous for opiate addiction?. BMJ. 2005, 331:1352-3. 10.1136\/bmj.331.7529.1352","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1089\/can.2021.0155","article-title":"Letter to the editor: cannabis as a solution to the opioid crisis: is the cart before the horse again?","volume":"7","author":"De Aquino JP","year":"2022","unstructured":"De Aquino JP, Bahji A, D'Souza DC. Letter to the editor: cannabis as a solution to the opioid crisis: is the cart before the horse again?. Cannabis Cannabinoid Res. 2022, 7:898-900. 10.1089\/can.2021.0155","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.outlook.2017.08.012","article-title":"The use of cannabis in response to the opioid crisis: a review of the literature","volume":"66","author":"Vyas MB","year":"2018","unstructured":"Vyas MB, LeBaron VT, Gilson AM. The use of cannabis in response to the opioid crisis: a review of the literature. Nurs Outlook. 2018, 66:56-65. 10.1016\/j.outlook.2017.08.012","journal-title":"Nurs Outlook"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2020.00737","article-title":"Opium alkaloids in harvested and thermally processed poppy seeds","volume":"8","author":"Carlin MG","year":"2020","unstructured":"Carlin MG, Dean JR, Ames JM. Opium alkaloids in harvested and thermally processed poppy seeds. Front Chem. 2020, 8:737. 10.3389\/fchem.2020.00737","journal-title":"Front Chem"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.100","article-title":"Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction","volume":"154","author":"Christie MJ","year":"2008","unstructured":"Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol. 2008, 154:384-96. 10.1038\/bjp.2008.100","journal-title":"Br J Pharmacol"},{"key":"ref18","article-title":"Opioid addiction","author":"Azadfard M","year":"2023","unstructured":"Azadfard M, Huecker MR, Leaming JM. Opioid addiction. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.258004","article-title":"Non-opioid neurotransmitter systems that contribute to the opioid withdrawal syndrome: a review of preclinical and human evidence","volume":"371","author":"Dunn KE","year":"2019","unstructured":"Dunn KE, Huhn AS, Bergeria CL, Gipson CD, Weerts EM. Non-opioid neurotransmitter systems that contribute to the opioid withdrawal syndrome: a review of preclinical and human evidence. J Pharmacol Exp Ther. 2019, 371:422-52. 10.1124\/jpet.119.258004","journal-title":"J Pharmacol Exp Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.110","article-title":"Neurocircuitry of addiction","volume":"35","author":"Koob GF","year":"2010","unstructured":"Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010, 35:217-38. 10.1038\/npp.2009.110","journal-title":"Neuropsychopharmacology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph8104025","article-title":"Considering the definition of addiction","volume":"8","author":"Sussman S","year":"2011","unstructured":"Sussman S, Sussman AN. Considering the definition of addiction. Int J Environ Res Public Health. 2011, 8:4025-38. 10.3390\/ijerph8104025","journal-title":"Int J Environ Res Public Health"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.983472","article-title":"Pharmacological treatments for drug misuse and dependence","volume":"16","author":"Reed K","year":"2015","unstructured":"Reed K, Day E, Keen J, Strang J. Pharmacological treatments for drug misuse and dependence. Expert Opin Pharmacother. 2015, 16:325-33. 10.1517\/14656566.2015.983472","journal-title":"Expert Opin Pharmacother"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00063","article-title":"The endocannabinoid system and cannabidiol's promise for the treatment of substance use disorder","volume":"10","author":"Chye Y","year":"2019","unstructured":"Chye Y, Christensen E, Solowij N, Y\u00fccel M. The endocannabinoid system and cannabidiol's promise for the treatment of substance use disorder. Front Psychiatry. 2019, 10:63. 10.3389\/fpsyt.2019.00063","journal-title":"Front Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2013.04.034","article-title":"Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal","volume":"248","author":"Scavone JL","year":"2013","unstructured":"Scavone JL, Sterling RC, Van Bockstaele EJ. Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience. 2013, 248:637-54. 10.1016\/j.neuroscience.2013.04.034","journal-title":"Neuroscience"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1151\/spp021113","article-title":"The neurobiology of opioid dependence: implications for treatment","volume":"1","author":"Kosten TR","year":"2002","unstructured":"Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002, 1:13-20. 10.1151\/spp021113","journal-title":"Sci Pract Perspect"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1089\/can.2021.0089","article-title":"Adjunctive management of opioid withdrawal with the nonopioid medication cannabidiol","volume":"7","author":"Kudrich C","year":"2022","unstructured":"Kudrich C, Hurd YL, Salsitz E, Wang AL. Adjunctive management of opioid withdrawal with the nonopioid medication cannabidiol. Cannabis Cannabinoid Res. 2022, 7:569-81. 10.1089\/can.2021.0089","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.09.013","article-title":"Role of the endocannabinoid system in drug addiction","volume":"157","author":"Manzanares J","year":"2018","unstructured":"Manzanares J, Caba\u00f1ero D, Puente N, Garc\u00eda-Guti\u00e9rrez MS, Grandes P, Maldonado R. Role of the endocannabinoid system in drug addiction. Biochem Pharmacol. 2018, 157:108-21. 10.1016\/j.bcp.2018.09.013","journal-title":"Biochem Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.03.022","article-title":"Contributions of serotonin in addiction vulnerability","volume":"61","author":"Kirby LG","year":"2011","unstructured":"Kirby LG, Zeeb FD, Winstanley CA. Contributions of serotonin in addiction vulnerability. Neuropharmacology. 2011, 61:421-32. 10.1016\/j.neuropharm.2011.03.022","journal-title":"Neuropharmacology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s40429-021-00361-z","article-title":"Suicide risk and addiction: the impact of alcohol and opioid use disorders","volume":"8","author":"Rizk MM","year":"2021","unstructured":"Rizk MM, Herzog S, Dugad S, Stanley B. Suicide risk and addiction: the impact of alcohol and opioid use disorders. Curr Addict Rep. 2021, 8:194-207. 10.1007\/s40429-021-00361-z","journal-title":"Curr Addict Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8369.1","article-title":"Neurobiology of opioid dependence in creating addiction vulnerability","volume":"5","author":"Evans CJ","year":"2016","unstructured":"Evans CJ, Cahill CM. Neurobiology of opioid dependence in creating addiction vulnerability. F1000Res. 2016, 5:10.12688\/f1000research.8369.1","journal-title":"F1000Res"},{"key":"ref31","unstructured":"AIHW. Opioid harm in Australia and comparisons between Australia and Canada. (2018). Accessed. December 5, 2023: https:\/\/www.aihw.gov.au\/reports\/illicit-use-of-drugs\/opioid-harm-in-australia\/summary."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2020.02.011","article-title":"pdate on the neuropsychiatry of substance use disorders","volume":"43","author":"Kolodner G","year":"2020","unstructured":"Kolodner G, Koliatsos VE. pdate on the neuropsychiatry of substance use disorders. Psychiatr Clin North Am. 2020, 43:291-304. 10.1016\/j.psc.2020.02.011","journal-title":"Psychiatr Clin North Am"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000711","article-title":"Cannabinoids for the treatment of opioid use disorder: where is the evidence?","volume":"15","author":"Suzuki J","year":"2021","unstructured":"Suzuki J, Weiss RD. Cannabinoids for the treatment of opioid use disorder: where is the evidence?. J Addict Med. 2021, 15:91-2. 10.1097\/ADM.0000000000000711","journal-title":"J Addict Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201300235","article-title":"Medication-assisted treatment with methadone: assessing the evidence","volume":"65","author":"Fullerton CA","year":"2014","unstructured":"Fullerton CA, Kim M, Thomas CP, et al.. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv. 2014, 65:146-57. 10.1176\/appi.ps.201300235","journal-title":"Psychiatr Serv"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub2","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick RP","year":"2004","unstructured":"Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2004, CD002207. 10.1002\/14651858.CD002207.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo L","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, et al.. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017, 357:j1550. 10.1136\/bmj.j1550","journal-title":"BMJ"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2017.1395855","article-title":"Medications for substance use disorders (SUD): emerging approaches","volume":"22","author":"Butelman ER","year":"2017","unstructured":"Butelman ER, Kreek MJ. Medications for substance use disorders (SUD): emerging approaches. Expert Opin Emerg Drugs. 2017, 22:301-15. 10.1080\/14728214.2017.1395855","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00742","article-title":"Management of opioid addiction with opioid substitution treatments: beyond methadone and buprenorphine","volume":"9","author":"Noble F","year":"2018","unstructured":"Noble F, Marie N. Management of opioid addiction with opioid substitution treatments: beyond methadone and buprenorphine. Front Psychiatry. 2018, 9:742. 10.3389\/fpsyt.2018.00742","journal-title":"Front Psychiatry"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12979","article-title":"The lived experience of Australian opioid replacement therapy recipients in a community-based program in regional Victoria","volume":"38","author":"Patil Vishwanath T","year":"2019","unstructured":"Patil Vishwanath T, Cash P, Cant R, Mummery J, Penney W. The lived experience of Australian opioid replacement therapy recipients in a community-based program in regional Victoria. Drug Alcohol Rev. 2019, 38:656-63. 10.1111\/dar.12979","journal-title":"Drug Alcohol Rev"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/164_2019_304","article-title":"Clinical trials for opioid use disorder","volume":"258","author":"Blessing E","year":"2020","unstructured":"Blessing E, Virani S, Rotrosen J. Clinical trials for opioid use disorder. Handb Exp Pharmacol. 2020, 258:167-202. 10.1007\/164_2019_304","journal-title":"Handb Exp Pharmacol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2008.59.8.909","article-title":"Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists","volume":"59","author":"Thomas CP","year":"2008","unstructured":"Thomas CP, Reif S, Haq S, Wallack SS, Hoyt A, Ritter GA. Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists. Psychiatr Serv. 2008, 59:909-16. 10.1176\/ps.2008.59.8.909","journal-title":"Psychiatr Serv"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c5475","article-title":"Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database","volume":"341","author":"Cornish R","year":"2010","unstructured":"Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ. 2010, 341:c5475. 10.1136\/bmj.c5475","journal-title":"BMJ"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.4103\/IJPSYM.IJPSYM_61_17","article-title":"A clinical study of opioid substitution therapy in a tertiary care center of Eastern India","volume":"39","author":"Mohapatra S","year":"2017","unstructured":"Mohapatra S, Nayak MR, Dash M. A clinical study of opioid substitution therapy in a tertiary care center of Eastern India. Indian J Psychol Med. 2017, 39:756-9. 10.4103\/IJPSYM.IJPSYM_61_17","journal-title":"Indian J Psychol Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-015-0373-7","article-title":"Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage","volume":"12","author":"Hurd YL","year":"2015","unstructured":"Hurd YL, Yoon M, Manini AF, Hernandez S, Olmedo R, Ostman M, Jutras-Aswad D. Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics. 2015, 12:807-15. 10.1007\/s13311-015-0373-7","journal-title":"Neurotherapeutics"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1089\/can.2018.0022","article-title":"Emerging evidence for cannabis' role in opioid use disorder","volume":"3","author":"Wiese B","year":"2018","unstructured":"Wiese B, Wilson-Poe AR. Emerging evidence for cannabis' role in opioid use disorder. Cannabis Cannabinoid Res. 2018, 3:179-89. 10.1089\/can.2018.0022","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2016.12.006","article-title":"Cannabidiol: swinging the marijuana pendulum from 'weed' to medication to treat the opioid epidemic","volume":"40","author":"Hurd YL","year":"2017","unstructured":"Hurd YL. Cannabidiol: swinging the marijuana pendulum from 'weed' to medication to treat the opioid epidemic. Trends Neurosci. 2017, 40:124-7. 10.1016\/j.tins.2016.12.006","journal-title":"Trends Neurosci"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2017.12.007","article-title":"Do medical marijuana laws reduce addictions and deaths related to pain killers?","volume":"58","author":"Powell D","year":"2018","unstructured":"Powell D, Pacula RL, Jacobson M. Do medical marijuana laws reduce addictions and deaths related to pain killers?. J Health Econ. 2018, 58:29-42. 10.1016\/j.jhealeco.2017.12.007","journal-title":"J Health Econ"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.4005","article-title":"Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010","volume":"174","author":"Bachhuber MA","year":"2014","unstructured":"Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med. 2014, 174:1668-73. 10.1001\/jamainternmed.2014.4005","journal-title":"JAMA Intern Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108005","article-title":"The impact of naturalistic cannabis use on self-reported opioid withdrawal","volume":"113","author":"Bergeria CL","year":"2020","unstructured":"Bergeria CL, Huhn AS, Dunn KE. The impact of naturalistic cannabis use on self-reported opioid withdrawal. J Subst Abuse Treat. 2020, 113:108005. 10.1016\/j.jsat.2020.108005","journal-title":"J Subst Abuse Treat"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-021-00468-6","article-title":"The association between cannabis use and outcome in pharmacological treatment for opioid use disorder","volume":"18","author":"Rosic T","year":"2021","unstructured":"Rosic T, Kapoor R, Panesar B, et al.. The association between cannabis use and outcome in pharmacological treatment for opioid use disorder. Harm Reduct J. 2021, 18:24. 10.1186\/s12954-021-00468-6","journal-title":"Harm Reduct J"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263583","article-title":"\"I got a bunch of weed to help me through the withdrawals\": naturalistic cannabis use reported in online opioid and opioid recovery community discussion forums","volume":"17","author":"Meacham MC","year":"2022","unstructured":"Meacham MC, Nobles AL, Tompkins DA, Thrul J. \"I got a bunch of weed to help me through the withdrawals\": naturalistic cannabis use reported in online opioid and opioid recovery community discussion forums. PLoS One. 2022, 17:e0263583. 10.1371\/journal.pone.0263583","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-019-0278-6","article-title":"Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients","volume":"16","author":"Lucas P","year":"2019","unstructured":"Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm Reduct J. 2019, 16:9. 10.1186\/s12954-019-0278-6","journal-title":"Harm Reduct J"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108586","article-title":"Current controversies in medical cannabis: recent developments in human clinical applications and potential therapeutics","volume":"191","author":"Schlag AK","year":"2021","unstructured":"Schlag AK, O'Sullivan SE, Zafar RR, Nutt DJ. Current controversies in medical cannabis: recent developments in human clinical applications and potential therapeutics. Neuropharmacology. 2021, 191:108586. 10.1016\/j.neuropharm.2021.108586","journal-title":"Neuropharmacology"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20054087","article-title":"Evidence from human studies for utilising cannabinoids for the treatment of substance-use disorders: a scoping review with a systematic approach","volume":"20","author":"Gharbi KA","year":"2023","unstructured":"Gharbi KA, Bonomo YA, Hallinan CM. Evidence from human studies for utilising cannabinoids for the treatment of substance-use disorders: a scoping review with a systematic approach. Int J Environ Res Public Health. 2023, 20:4087. 10.3390\/ijerph20054087","journal-title":"Int J Environ Res Public Health"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.108948","article-title":"Cannabidiol and substance use disorder: dream or reality","volume":"207","author":"Karimi-Haghighi S","year":"2022","unstructured":"Karimi-Haghighi S, Razavi Y, Iezzi D, Scheyer AF, Manzoni O, Haghparast A. Cannabidiol and substance use disorder: dream or reality. Neuropharmacology. 2022, 207:108948. 10.1016\/j.neuropharm.2022.108948","journal-title":"Neuropharmacology"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2012.684624","article-title":"Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain","volume":"44","author":"Lucas P","year":"2012","unstructured":"Lucas P. Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain. J Psychoactive Drugs. 2012, 44:125-33. 10.1080\/02791072.2012.684624","journal-title":"J Psychoactive Drugs"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial","volume":"176","author":"Hurd YL","year":"2019","unstructured":"Hurd YL, Spriggs S, Alishayev J, et al.. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry. 2019, 176:911-22. 10.1176\/appi.ajp.2019.18101191","journal-title":"Am J Psychiatry"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000118","article-title":"Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans","volume":"9","author":"Manini AF","year":"2015","unstructured":"Manini AF, Yiannoulos G, Bergamaschi MM, et al.. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med. 2015, 9:204-10. 10.1097\/ADM.0000000000000118","journal-title":"J Addict Med"},{"key":"ref59","article-title":"Medicinal Cannabis for Treatment of Chronic Pain","author":"Bains S","year":"2022","unstructured":"Bains S, Mukhdomi T. Medicinal Cannabis for Treatment of Chronic Pain. StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.31128\/AJGP-04-21-5939","article-title":"Medicinal cannabis in the treatment of chronic pain","volume":"50","author":"Henderson LA","year":"2021","unstructured":"Henderson LA, Kotsirilos V, Cairns EA, Ramachandran A, Peck CC, McGregor IS. Medicinal cannabis in the treatment of chronic pain. Aust J Gen Pract. 2021, 50:724-32. 10.31128\/AJGP-04-21-5939","journal-title":"Aust J Gen Pract"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2019.08.002","article-title":"Cannabidiol (CBD) use in psychiatric disorders: a systematic review","volume":"74","author":"Bonaccorso S","year":"2019","unstructured":"Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Cannabidiol (CBD) use in psychiatric disorders: a systematic review. Neurotoxicology. 2019, 74:282-98. 10.1016\/j.neuro.2019.08.002","journal-title":"Neurotoxicology"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1089\/imr.2022.0070","article-title":"Cannabidiol effect on cue-induced craving for individuals with opioid use disorder treated with buprenorphine: a small proof-of-concept open-label study","volume":"1","author":"Suzuki J","year":"2022","unstructured":"Suzuki J, Martin B, Prostko S, Chai PR, Weiss RD. Cannabidiol effect on cue-induced craving for individuals with opioid use disorder treated with buprenorphine: a small proof-of-concept open-label study. Integr Med Rep. 2022, 1:157-63. 10.1089\/imr.2022.0070","journal-title":"Integr Med Rep"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1155984","article-title":"Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: a pilot, double-blind, placebo-controlled, randomized cross-over trial","volume":"14","author":"Suzuki J","year":"2023","unstructured":"Suzuki J, Prostko S, Szpak V, et al.. Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: a pilot, double-blind, placebo-controlled, randomized cross-over trial. Front Psychiatry. 2023, 14:1155984. 10.3389\/fpsyt.2023.1155984","journal-title":"Front Psychiatry"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209031","article-title":"Differential effect of cannabis use on opioid agonist treatment outcomes: exploratory analyses from the OPTIMA study","volume":"149","author":"Elkrief L","year":"2023","unstructured":"Elkrief L, Bastien G, McAnulty C, et al.. Differential effect of cannabis use on opioid agonist treatment outcomes: exploratory analyses from the OPTIMA study. J Subst Use Addict Treat. 2023, 149:209031. 10.1016\/j.josat.2023.209031","journal-title":"J Subst Use Addict Treat"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19090918","article-title":"Cannabidiol: not a cure-all, but a candidate for coping with cue-induced craving","volume":"176","author":"Epstein DH","year":"2019","unstructured":"Epstein DH. Cannabidiol: not a cure-all, but a candidate for coping with cue-induced craving. Am J Psychiatry. 2019, 176:888-91. 10.1176\/appi.ajp.2019.19090918","journal-title":"Am J Psychiatry"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-021-00941-8","article-title":"Recent advances in the treatment of opioid use disorder","volume":"25","author":"Kuppalli S","year":"2021","unstructured":"Kuppalli S, Seth R, Orhurhu V, et al.. Recent advances in the treatment of opioid use disorder. Curr Pain Headache Rep. 2021, 25:23. 10.1007\/s11916-021-00941-8","journal-title":"Curr Pain Headache Rep"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-020-0835-4","article-title":"The role of cannabidiol (CBD) in chronic pain management: an assessment of current evidence","volume":"24","author":"Boyaji S","year":"2020","unstructured":"Boyaji S, Merkow J, Elman RN, Kaye AD, Yong RJ, Urman RD. The role of cannabidiol (CBD) in chronic pain management: an assessment of current evidence. Curr Pain Headache Rep. 2020, 24:4. 10.1007\/s11916-020-0835-4","journal-title":"Curr Pain Headache Rep"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.33181\/13022","article-title":"Cannabidiol: background and literature review of potential treatments","volume":"13","author":"Kolongowski B","year":"2021","unstructured":"Kolongowski B, Tjiattas-Saleski L. Cannabidiol: background and literature review of potential treatments. Osteopath Fam Physician. 2021, 13:16-23. 10.33181\/13022","journal-title":"Osteopath Fam Physician"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.2174\/1389201020666191202111534","article-title":"The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities","volume":"21","author":"Xu DH","year":"2020","unstructured":"Xu DH, Cullen BD, Tang M, Fang Y. The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. Curr Pharm Biotechnol. 2020, 21:390-402. 10.2174\/1389201020666191202111534","journal-title":"Curr Pharm Biotechnol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.2004.03674.x","article-title":"Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies","volume":"59","author":"Notcutt W","year":"2004","unstructured":"Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia. 2004, 59:440-52. 10.1111\/j.1365-2044.2004.03674.x","journal-title":"Anaesthesia"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001464","article-title":"An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia","volume":"160","author":"van de Donk T","year":"2019","unstructured":"van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019, 160:860-9. 10.1097\/j.pain.0000000000001464","journal-title":"Pain"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1197388","article-title":"Editorial: opioid overdose and harm reduction approaches to combat the looming crisis","volume":"14","author":"Gunturu S","year":"2023","unstructured":"Gunturu S, Jaka S. Editorial: opioid overdose and harm reduction approaches to combat the looming crisis. Front Psychiatry. 2023, 14:1197388. 10.3389\/fpsyt.2023.1197388","journal-title":"Front Psychiatry"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1159\/000521683","article-title":"Therapeutic potential of cannabis, cannabidiol, and cannabinoid-based pharmaceuticals","volume":"107","author":"Legare CA","year":"2022","unstructured":"Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic potential of cannabis, cannabidiol, and cannabinoid-based pharmaceuticals. Pharmacology. 2022, 107:131-49. 10.1159\/000521683","journal-title":"Pharmacology"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19063336","article-title":"Public health implications of cannabis legalization: an exploration of adolescent use and evidence-based interventions","volume":"19","author":"Donnelly J","year":"2022","unstructured":"Donnelly J, Young M, Marshall B, Hecht ML, Saldutti E. Public health implications of cannabis legalization: an exploration of adolescent use and evidence-based interventions. Int J Environ Res Public Health. 2022, 19:3336. 10.3390\/ijerph19063336","journal-title":"Int J Environ Res Public Health"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/214898-the-therapeutic-potential-of-cannabidiol-in-revolutionising-opioid-use-disorder-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:28Z","timestamp":1707509428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/214898-the-therapeutic-potential-of-cannabidiol-in-revolutionising-opioid-use-disorder-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,16]]},"references-count":74,"URL":"https:\/\/doi.org\/10.7759\/cureus.50634","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,16]]}}}